Johns Hopkins ABX Guide
Miltefosine
INDICATIONS
FDA
FDA
- Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.
- Miltefosine no longer needs to be obtained through the CDC.
- See www.impavido.com or call 407-270-7790 for ordering information.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of free-living amoeba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
- Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 3, 2019
Citation
Dzintars, Kathryn. "Miltefosine." Johns Hopkins ABX Guide, The Johns Hopkins University, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540350/all/Miltefosine.
Dzintars K. Miltefosine. Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540350/all/Miltefosine. Accessed November 21, 2024.
Dzintars, K. (2019). Miltefosine. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540350/all/Miltefosine
Dzintars K. Miltefosine [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. [cited 2024 November 21]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540350/all/Miltefosine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Miltefosine
ID - 540350
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2019/09/03/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540350/all/Miltefosine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
